Biogen admits slow Aduhelm launch, as scientists question label againShares in Biogen have come under pressure after chief executive Michel Vounatsos admitted that the company is facing Share XBiogen admits slow Aduhelm launch, as scientists question label againhttps://pharmaphorum.com/news/biogen-admits-slow-aduhelm-launch-as-scientists-question-label-again/
Startup Neuroglee raises $10m for virtual neurology clinicsA digital health company focusing on neurodegenerative disorders – Neuroglee Therapeutics – has raised $10 million in first-round Share XStartup Neuroglee raises $10m for virtual neurology clinicshttps://pharmaphorum.com/news/startup-neuroglee-raises-10m-for-virtual-neurology-clinics/
AC Immune claims half a win for tau drug in Alzheimer’s trialShares in AC Immune leaped today after the company said its tau-targeting Alzheimer’s disease candidate semorinemab hit one Share XAC Immune claims half a win for tau drug in Alzheimer’s trialhttps://pharmaphorum.com/news/ac-immune-claims-half-a-win-for-tau-drug-in-alzheimers-trial/
US health insurer will not fund Biogen, Eisai’s Alzheimer’s drug AduhelmHealth insurer Excellus BlueCross BlueShield has said it will not cover treatment with Biogen and Eisai’s new Alzheimer’s Share XUS health insurer will not fund Biogen, Eisai’s Alzheimer’s drug Aduhelmhttps://pharmaphorum.com/news/health-insurer-excellus-will-not-fund-alzheimers-drug-aduhelm/
Cambridge team says AI could diagnose dementia with one scanResearchers at Cambridge University in the UK are trialling an artificial intelligence system that they think could spot Share XCambridge team says AI could diagnose dementia with one scanhttps://pharmaphorum.com/news/cambridge-teams-says-ai-could-diagnose-dementia-with-one-scan/
Lilly sets out its stall on donanemab as filing approachesThe FDA’s approval of Biogen’s Aduhelm for Alzheimer’s disease has emboldened Eli Lilly to move forward plans to Share XLilly sets out its stall on donanemab as filing approacheshttps://pharmaphorum.com/news/lilly-sets-out-its-stall-on-donanemab-as-filing-approaches/
NIH digital tool aims to boost enrolment into Alzheimer’s studiesWith a string of new drugs for Alzheimer’s disease making their way through late-stage clinical testing, the demand Share XNIH digital tool aims to boost enrolment into Alzheimer’s studieshttps://pharmaphorum.com/news/nih-digital-tool-aims-to-boost-enrolment-into-alzheimers-studies/
Biogen adds real-world test for Aduhelm to its confirmatory trialBiogen and partner Eisai have said they will run a large-scale observational study of Alzheimer’s drug Aduhelm in Share XBiogen adds real-world test for Aduhelm to its confirmatory trialhttps://pharmaphorum.com/news/biogen-adds-real-world-test-for-aduhelm-to-its-confirmatory-trial/
Biogen bites back at critics of Aduhelm after drug’s slow startBiogen has reported $2m in sales for newly-launched Alzheimer’s therapy Aduhelm that came in below its expectations, prompting Share XBiogen bites back at critics of Aduhelm after drug’s slow starthttps://pharmaphorum.com/news/biogen-bites-back-at-critics-of-aduhelm-after-drugs-slow-start/
